Measured by its ability to inhibit recombinant human BMP-2 induced alkaline phosphatase production by C2C12 myogenic cells. The ED50 for this effect is typically 1-3 ug/ml in the presence of 500 ng/ml of recombinant human BMP-2 corresponding to a Specific Activity of 2,000IU/mg.
CD292 was lyophilized from a concentrated (1mg/ml) sterile solution containing 1X PBS.
Sterile Filtered White lyophilized (freeze-dried) powder.
Greater than 90.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
It is recommended to reconstitute the lyophilized ALK-3 in sterile PBS not less than 100 ug/ml, which can then be further diluted to other aqueous solutions.
Lyophilized Bone Morphogenetic Protein Receptor 1A although stable at room temperature for 3 weeks, should be stored desiccated below
-18oC. Upon reconstitution BMPR1A should be stored at 4oC between 2-7 days and for future use below -18oC.
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please prevent freeze-thaw cycles.
BMPR-1A, BMP-R1A, BMPR1A, BMR1A, CD292, CD-292, Serine/threonine-protein kinase receptor R5, SKR5, Activin receptor-like kinase 3, ALK-3, ACVRLK3, EC 2.7.11.30, CD292 antigen.
